News

UCSF and BridgeBio Pharma to Accelerate Therapies for Genetic Diseases

SAN FRANCISCO – December 23, 2020 - UC San Francisco and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.

Autobahn Collaboration to Accelerate UCSF Innovation from Bench to Bedside

Partnership with Autobahn Labs Aims to Pave Road Through ‘Valley of Death’ Faced by Novel Therapies

UCSF Startup Siolta and Bio-Me to Collaborate

Bio-Me and UCSF startup Siolta Therapeutics, founded by Professor Susan Lynch, aim to develop and market predictive test for infants to determine microbiome-based pediatric allergies and asthma. More

Epygenix Therapeutics Announces Phase 2 of Zebrafish Study

Epygenix Therapeutics, Inc., a privately-held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the first patient has been enrolled in a Phase 2, 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of EPX-100 as...

PrinterPrezz Receives Clearance for 3D Printed Spine Devices Based on UCSF Technology

PrinterPrezz, Inc., a medical polymer and metal 3D printing, nanotechnologies and implant design company, today announced the U.S. Food and Drug Administration (FDA) clearance of the company’s 510(k) for the PrinterPrezz GAIA™ Lumbar Interbody Fusion Device (LIFD) family of spine implants as a...

UC Berkeley’s Jennifer Doudna wins 2020 Nobel Prize in Chemistry

University of California, Berkeley, biochemist Jennifer Doudna today won the 2020 Nobel Prize in Chemistry, sharing it with colleague Emmanuelle Charpentier for the co-development of CRISPR-Cas9, a genome editing breakthrough that has revolutionized biomedicine. More

UCSF Health Hub Announces Winners of the Digital Health Awards

GoodRx, Conversa Health, Ginger& Grand Rounds Among Companies Honored by Expert Judges in Medicine & Venture Capital

Sanofi Acquires Principia Biopharma in $3.6 Billion Deal

Sanofi SA will acquire Principia Biopharma Inc. in a $3.68 billion deal that brings Sanofi three clinical-stage BTK inhibitors and simplifies a partnership that began three years ago.

‘AeroNabs’ Promise Powerful, Inhalable Protection Against COVID-19

Led by UCSF graduate student Michael Schoof, a team of researchers engineered a completely synthetic, production-ready molecule that straitjackets the crucial SARS-CoV-2 machinery that allows the virus to infect our cells.

Printerprezz and UCSF Enter Exclusive License Agreement

PrinterPrezz announced the exclusive, worldwide license of Spinal Interbody Device technology patent rights from the University of California, San Francisco. More